Top 10 Cancers of America

Here are the most common cancers in the United States. Most of these statistics were compiled in the American Cancer Society Facts & Figures annual report for 2013:

1 – Skin cancer

Skin cancer is divided into the non-melanoma and melanoma categories. Non-melanoma (basal cell and squamous cell skin cancer) is the more common form with over 2,000,000 cases expected to be diagnosed in the country in 2012. Most of these forms of cancer are curable. Melanoma, on the other hand, is the more serious type of skin cancer. It affects approximately five percent of people diagnosed with skin cancer, but is attributed to over 75 percent of all skin cancer deaths. In 2012, 76,250 new cases of melanoma were expected to be diagnosed.

Nuformix plc (LON:NFX) is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology using drug repurposing.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Nuformix plc

More articles like this

Nuformix plc

Nuformix Plc Receives Second NXP001 Milestone Payment from Oxilio

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company has achieved the second milestone according to its updated NXP001 exclusive licensing agreement with Oxilio

Nuformix plc

Nuformix hosting online Q&A session on 13 June 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company’s Executive Director, Dr Dan Gooding, will be hosting an online Q&A session at 5.30

Nuformix plc

Nuformix appoints Kreston Reeves as auditor

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the appointment of Kreston Reeves LLP as auditor to the Company. The appointment of Kreston Reeves

Nuformix plc

Nuformix delighted with NXP002 study results

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a

Nuformix plc

Nuformix updates on the NXP002 programme for treatment of IPF

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a